Literature DB >> 26395285

Comparison of manual hematocrit determinations versus automated methods for hematopoietic progenitor cell apheresis products.

Scott T Avecilla1, Steven M Marionneaux1, Tyler D Leiva1, Jo-Ann Tonon1, Virgil T Chan1, Christine Moung1, Richard C Meagher1, Peter Maslak1.   

Abstract

BACKGROUND: Allogeneic hematopoietic stem cell donor selection is based primarily on human leukocyte antigen degree of match and it often occurs without regard to the red blood cell (RBC) compatibility between donor and recipient. When major ABO-mismatched grafts are infused, it is imperative that an accurate determination of the incompatible RBC content is made to ensure that the product is safe for infusion. RBC content determination requires the hematocrit (Hct) parameter which can be obtained via manual (directly measured) or automated (calculated) methods. STUDY DESIGN AND METHODS: Ninety-seven apheresis hematopoietic progenitor grafts were assessed for Hct by manual testing and by four commercially available automated hematology analyzer instruments. A clinical model was developed to assess the frequency of unnecessary RBC reductions or alteration in standard infusion practice.
RESULTS: Significant (p < 0.001) differences were observed where the manual Hct value was markedly lower than automated Hct values. At stringent incompatible RBC threshold of 10 mL, the number of preventable RBC reduction procedures ranged from 18% to 69%.
CONCLUSION: Accurate determination of RBC content of hematopoietic progenitor grafts is essential for patient safety. Despite the rapidity and convenience offered by automated Hct methods, they significantly overestimate the incompatible RBC content of grafts, which may trigger unnecessary RBC reduction procedures or split infusions. In products where automated Hct methods indicate excessive amounts of incompatible RBCs are present, we advise the performance of confirmatory testing with a manual Hct method to ensure that the automated Hct value is not a false positive.
© 2015 AABB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26395285      PMCID: PMC4980147          DOI: 10.1111/trf.13346

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  ABO-incompatible marrow transplants.

Authors:  C D Buckner; R A Clift; J E Sanders; B Williams; M Gray; R Storb; E D Thomas
Journal:  Transplantation       Date:  1978-10       Impact factor: 4.939

Review 2.  Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation.

Authors:  S D Rowley; M L Donato; P Bhattacharyya
Journal:  Bone Marrow Transplant       Date:  2011-09       Impact factor: 5.483

3.  ABO-incompatible marrow transplants.

Authors:  W I Bensinger; C D Buckner; E D Thomas; R A Clift
Journal:  Transplantation       Date:  1982-04       Impact factor: 4.939

Review 4.  Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation.

Authors:  Mark H Yazer; Darrell J Triulzi
Journal:  Curr Opin Hematol       Date:  2007-11       Impact factor: 3.284

5.  Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different?

Authors:  Cesar Homero Gutiérrez-Aguirre; Andrés Gómez-De-León; Julio Alatorre-Ricardo; Olga Graciela Cantú-Rodríguez; Oscar González-Llano; José Carlos Jaime-Pérez; Consuelo Mancías-Guerra; Juan Antonio Flores-Jiménez; David Gómez-Almaguer
Journal:  Transfusion       Date:  2013-10-28       Impact factor: 3.157

  5 in total
  2 in total

1.  A Nomogram for the Rapid Prediction of Hematocrit Following Blood Loss and Fluid Shifts in Neonates, Infants, and Adults.

Authors:  Francesco M Egro; Elizabeth M Kenny; Ernest C Manders; Ernest Manders
Journal:  Cureus       Date:  2020-04-22

2.  Process and procedural adjustments to improve CD34+ collection efficiency of hematopoietic progenitor cell collections in sickle cell disease.

Authors:  Scott T Avecilla; Farid Boulad; Karina Yazdanbakhsh; Michel Sadelain; Patricia A Shi
Journal:  Transfusion       Date:  2021-06-23       Impact factor: 3.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.